The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
Abstract Introduction Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (V...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.664 |
| _version_ | 1811329991485423616 |
|---|---|
| author | Tao Ma Songning Ding Rui Huang Hengxue Wang Junjun Wang Jiacheng Liu Jian Wang Jie Li Chao Wu Huafeng Fan Nan Zhou |
| author_facet | Tao Ma Songning Ding Rui Huang Hengxue Wang Junjun Wang Jiacheng Liu Jian Wang Jie Li Chao Wu Huafeng Fan Nan Zhou |
| author_sort | Tao Ma |
| collection | DOAJ |
| description | Abstract Introduction Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in the postvaccination era. Methods The epidemiology and clinical data of cases with confirmed SARS‐CoV‐2 Delta VOC infection were retrospective collected. Dates of the first positive PCR test were collected to estimate the distribution of latent period. Results Of the 40 patients, 16 were male (40%). The median age of patients was 47.5 years. The median latent period of patients was 6.0 days (interquartile range [IQR], 4.0−9.0 days) and the longest latent period was 13.0 days after exposure. The latent periods were longer in male patients compared to female patients (median, 8.5 days vs. 5.0 days, p = .041). The median latent period was comparable among fully vaccinated cases (6.5 days), no vaccinated cases (7.5 days), and partially vaccinated cases (5.5 days). Conclusions The median latent period of SARS‐CoV‐2 Delta VOC infection was 6.0 days. The latent period between vaccinated and non‐vaccinated patients was not significantly different. The 14‐day quarantine program is sufficient to prevent the transmission of COVID‐19 by Delta VOC in the postvaccination era. |
| first_indexed | 2024-04-13T15:53:32Z |
| format | Article |
| id | doaj.art-e01ba8488e9d4b309f1eb393bf016e96 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-04-13T15:53:32Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-e01ba8488e9d4b309f1eb393bf016e962022-12-22T02:40:46ZengWileyImmunity, Inflammation and Disease2050-45272022-07-01107n/an/a10.1002/iid3.664The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination eraTao Ma0Songning Ding1Rui Huang2Hengxue Wang3Junjun Wang4Jiacheng Liu5Jian Wang6Jie Li7Chao Wu8Huafeng Fan9Nan Zhou10Department of Acute Infectious Disease Control and Prevention Nanjing Municipal Center for Disease Control and Prevention Nanjing ChinaDepartment of Acute Infectious Disease Control and Prevention Nanjing Municipal Center for Disease Control and Prevention Nanjing ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing ChinaDepartment of Acute Infectious Disease Control and Prevention Nanjing Municipal Center for Disease Control and Prevention Nanjing ChinaDepartment of Acute Infectious Disease Control and Prevention Nanjing Municipal Center for Disease Control and Prevention Nanjing ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine Nanjing University of Chinese Medicine Nanjing Jiangsu ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing ChinaMicrobiology Laboratory Nanjing Municipal Center for Disease Control and Prevention Nanjing ChinaDepartment of Acute Infectious Disease Control and Prevention Nanjing Municipal Center for Disease Control and Prevention Nanjing ChinaAbstract Introduction Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in the postvaccination era. Methods The epidemiology and clinical data of cases with confirmed SARS‐CoV‐2 Delta VOC infection were retrospective collected. Dates of the first positive PCR test were collected to estimate the distribution of latent period. Results Of the 40 patients, 16 were male (40%). The median age of patients was 47.5 years. The median latent period of patients was 6.0 days (interquartile range [IQR], 4.0−9.0 days) and the longest latent period was 13.0 days after exposure. The latent periods were longer in male patients compared to female patients (median, 8.5 days vs. 5.0 days, p = .041). The median latent period was comparable among fully vaccinated cases (6.5 days), no vaccinated cases (7.5 days), and partially vaccinated cases (5.5 days). Conclusions The median latent period of SARS‐CoV‐2 Delta VOC infection was 6.0 days. The latent period between vaccinated and non‐vaccinated patients was not significantly different. The 14‐day quarantine program is sufficient to prevent the transmission of COVID‐19 by Delta VOC in the postvaccination era.https://doi.org/10.1002/iid3.664latent periodsevere acute respiratory syndrome coronavirus 2vaccinevariant of concern |
| spellingShingle | Tao Ma Songning Ding Rui Huang Hengxue Wang Junjun Wang Jiacheng Liu Jian Wang Jie Li Chao Wu Huafeng Fan Nan Zhou The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era Immunity, Inflammation and Disease latent period severe acute respiratory syndrome coronavirus 2 vaccine variant of concern |
| title | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
| title_full | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
| title_fullStr | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
| title_full_unstemmed | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
| title_short | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
| title_sort | latent period of coronavirus disease 2019 with sars cov 2 b 1 617 2 delta variant of concern in the postvaccination era |
| topic | latent period severe acute respiratory syndrome coronavirus 2 vaccine variant of concern |
| url | https://doi.org/10.1002/iid3.664 |
| work_keys_str_mv | AT taoma thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT songningding thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT ruihuang thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT hengxuewang thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT junjunwang thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT jiachengliu thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT jianwang thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT jieli thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT chaowu thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT huafengfan thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT nanzhou thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT taoma latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT songningding latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT ruihuang latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT hengxuewang latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT junjunwang latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT jiachengliu latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT jianwang latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT jieli latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT chaowu latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT huafengfan latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT nanzhou latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera |